OptimizeRx CorporationOPRXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 79% recommend buying.

Consensus Rating

Buy

14 analysts·Moderate coverage

79%

Rating Distribution

Strong Buy

00%

Buy

1179%

Hold

321%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 118% higher.

Bear Case

$23.00

+118%

Consensus

$23.00

+118%

Bull Case

$23.00

+118%

Price Range14 analysts

Low

Consensus

High

$23.00

Current Target

Current Price

$10.54

Upside to Target

$12.46

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.86(5 analysts)

P/E5741x

Current: 5741.1x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+9.37%

EPS+17.11%

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+180.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 10, 2025UBS

OptimizeRx price target raised to $23 from $20 at Citizens JMP

Target:$23.00

+25.8%from $18.29

Apr 4, 2024JMP Securities

JMP Securities Starts OptimizeRX (OPRX) at Market Outperform, 'Comprehensive Biopharma Digital Marketing Platform'

Target:$15.00

+34.3%from $11.17

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance